sorafenib has been researched along with transferrin in 3 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (transferrin) | Trials (transferrin) | Recent Studies (post-2010) (transferrin) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 17,596 | 554 | 3,141 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Hanumanthu, PL; Keechilat, P; Koyakutty, M; Malarvizhi, GL; Menon, D; Menon, K; Mony, U; Nair, S; Prabhu, R; Retnakumari, AP; Sidharthan, N; Thampi, MV | 1 |
Koyakutty, M; Malarvizhi, GL; Nair, S; Retnakumari, AP | 1 |
Chen, D; Fu, J; Hu, H; Li, W; Xin, X | 1 |
3 other study(ies) available for sorafenib and transferrin
Article | Year |
---|---|
Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Nanomedicine; Nanoparticles; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Real-Time Polymerase Chain Reaction; Receptors, Transferrin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serum Albumin; Sorafenib; STAT5 Transcription Factor; Transferrin; Tumor Cells, Cultured | 2012 |
Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Doxorubicin; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms; Nanomedicine; Niacinamide; Phenylurea Compounds; Sorafenib; Transferrin | 2014 |
Transferrin-Modified Nanoliposome Codelivery Strategies for Enhancing the Cancer Therapy.
Topics: Animals; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Humans; Liposomes; Mice; Mice, Inbred BALB C; Neoplasms; Sorafenib; Transferrin | 2020 |